GLP-1 bone density decline: 255 patients over 34 months of real-world data

TL;DR

A real-world retrospective study from Weill Cornell Medical College followed 255 patients on semaglutide or tirzepatide for an average of 34 months. Bone mineral density fell at every measured site: lumbar spine by 1.6%, femoral neck by 1.8%, and total hip by 2.8%. Thirteen percent developed new fractures. Patients with diabetes had three times the fracture rate of non-diabetic patients. Greater weight loss correlated directly with steeper hip bone density decline.

The weight loss is real. The cardiovascular benefits are real. But for a growing number of patients now entering their third and fourth year on GLP-1 medications, bone health is emerging as a serious concern that most were never warned about when they started treatment. A Weill Cornell study presented at the Journal of the Endocrine Society in late 2025 gives the clearest real-world picture yet of what happens to your skeleton on long-term GLP-1 therapy.

Why GLP-1 medications might affect bone density

Bone loss on GLP-1 therapy is not surprising once you understand the mechanisms. Several factors converge to create skeletal risk:

• Caloric restriction - reduced food intake lowers calcium, vitamin D, vitamin K, and protein, all essential for bone formation
• Rapid weight loss - every kilogram of weight lost reduces mechanical loading on the skeleton, which is one of the key signals bones use to maintain density
• Muscle loss - GLP-1 medications cause 30-40% of weight lost to come from lean mass in many patients; less muscle means less bone-protective load
• GLP-1 receptor effects on bone - GLP-1 receptors exist in osteoblasts (bone-building cells), and the effects of pharmacological GLP-1 agonism on bone remodelling are still being mapped

The pattern resembles what researchers have documented after bariatric surgery - significant weight loss rapidly improving metabolic health while simultaneously accelerating bone loss. GLP-1 medications produce bariatric-surgery-level weight loss in some patients, and appear to produce bariatric-surgery-comparable skeletal effects.

The Weill Cornell study: who was followed and for how long

The retrospective review enrolled 255 patients across Weill Cornell Medical College who had used semaglutide or tirzepatide for at least six months and had two bone mineral density (BMD) scans performed on identical equipment at baseline and follow-up. Average follow-up was 34 months - nearly three years - making this one of the longest real-world bone density datasets for GLP-1 medications to date.

The cohort was predominantly female (92%), predominantly white (63%), with a mean age of 68 years and a mean BMI of 31.2 kg/m². Three-quarters had osteopenia or osteoporosis at baseline - already compromised skeletal health before starting GLP-1 medications. Twenty-seven percent had prior fragility fractures. Average weight loss over the study period was 7.0%.

What happened to bone density

Bone mineral density declined at every measured site:

• Lumbar spine: -1.6% over 34 months
• Femoral neck: -1.8%
• Total hip: -2.8% (p < 0.001 - highly statistically significant)

The total hip decline is clinically meaningful. A 2.8% reduction in hip BMD over three years represents accelerated loss compared to normal ageing rates. For someone already in the osteopenia range, this brings them closer to osteoporosis - and osteoporosis means fractures.

Fractures: 13% of patients developed new breaks

Thirteen percent of the 255 patients developed new fractures during the 34-month follow-up period - 33 people. The fracture sites were not specified in the abstract, but in populations with this age and BMD profile, hip, vertebral, and wrist fractures are the most common fragility fractures.

The fracture rate differed dramatically by diabetes status:

• Patients with diabetes: 20.5% fracture rate over 34 months
• Patients without diabetes: 7.0% fracture rate
• That is a three-fold higher fracture risk in diabetic patients (p = 0.0014)

Diabetes itself is an independent risk factor for fractures - diabetic bone disease involves alterations in collagen cross-linking that make bone more brittle regardless of BMD. GLP-1 medications appear to compound this underlying vulnerability.

The weight loss-bone loss connection

One of the most important findings was the direct correlation between weight loss and hip BMD decline. Pearson correlation coefficient: r = 0.35, p < 0.001. In plain terms: patients who lost more weight lost more hip bone density. Every additional percentage point of weight lost predicted additional bone density loss at the hip.

This is a finding with real practical implications. The patients achieving the most dramatic results on GLP-1 medications - losing 15%, 20%, or more of body weight - may be at greatest skeletal risk. The very outcome that patients and prescribers celebrate is the same outcome that predicts the most bone loss.

What you can actually do about it

Bone loss on GLP-1 medications is real, but it is not inevitable and it is not unmodifiable. Based on what research has established about bone-protective interventions in similar populations:

• Resistance training - loading the skeleton through weight-bearing exercise is the most powerful stimulus for bone formation. Two to three sessions per week at minimum, targeting major muscle groups
• Adequate protein intake - bone matrix is partly protein; the 1.2 g/kg/day protein target for GLP-1 users also supports bone health
• Vitamin D and calcium - both are essential for bone mineralisation and frequently deficient in GLP-1 users due to reduced food intake
• Vitamin K2 - directs calcium into bone rather than arteries; often overlooked in standard supplement advice
• Bone density monitoring - if you have been on a GLP-1 medication for two or more years, a DEXA scan is a reasonable conversation to have with your prescriber

Calcium and vitamin D supplementation alone is not sufficient if you are not absorbing them. GLP-1 medications alter gastric emptying in ways that may affect the timing of nutrient absorption - another reason why targeted supplementation designed for this population matters. GLP-1 Shield includes vitamin D and vitamin K2 alongside other nutrients specifically documented as deficient in GLP-1 users.

Frequently asked questions

Do Ozempic and Wegovy cause bone loss?

Real-world data suggests yes. A 34-month Weill Cornell study of 255 patients on semaglutide or tirzepatide found bone density fell at every measured site, with total hip BMD declining by 2.8% on average. The effect correlated directly with the amount of weight lost - greater weight loss predicted greater bone density decline. Clinical trials and systematic reviews are now consistently showing this pattern.

Who is most at risk for fractures on GLP-1 medications?

Patients with diabetes had three times the fracture rate of non-diabetic patients (20.5% vs 7.0%) in the Weill Cornell study. People who are already in the osteopenia or osteoporosis range, women over 60, those with prior fragility fractures, and patients achieving rapid large weight loss are all at higher risk. These groups should discuss bone density monitoring with their prescriber.

What vitamins should I take to protect my bones on GLP-1 medications?

Vitamin D, calcium, vitamin K2, and magnesium are the most important bone-protective nutrients. Protein intake at or above 1.2 g/kg/day also supports bone matrix. GLP-1 medications reduce food intake, making it harder to meet these targets through diet alone. A supplement formulated specifically for GLP-1 users - like GLP-1 Shield - covers these gaps more precisely than a standard multivitamin.

Should I get a DEXA scan if I am on semaglutide or tirzepatide?

If you have been on a GLP-1 medication for two or more years, have lost significant weight (10%+ of body weight), or have other risk factors for osteoporosis (female, over 55, prior fracture, diabetes), a DEXA scan conversation with your prescriber is reasonable. Routine DEXA monitoring is not yet standard of care for GLP-1 users, but early findings like this Weill Cornell study are pushing the field in that direction.